Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Compass Pathways Plc

Healthcare US CMPS

12.08USD
0.67(5.87%)

Last update at 2026-06-12T20:16:00Z

Day Range

11.4512.37
LowHigh

52 Week Range

2.2510.21
LowHigh

Fundamentals

  • Previous Close 11.41
  • Market Cap1276.37M
  • Volume2510076
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-175.07400M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-3.08

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -290.33500M -153.52800M -117.68400M -91.09700M -71.54300M
Minority interest - - - - -
Net income -287.86200M -155.12200M -118.46400M -91.50500M -71.74200M
Selling general administrative 60.60M 59.17M 49.40M 45.35M 39.19M
Selling and marketing expenses - - 0.05M - -
Gross profit -0.21650M -0.23310M -0.24294M - -
Reconciled depreciation 0.22M 0.23M 0.44M 0.33M 0.17M
Ebit -179.25350M -149.04900M -115.48000M -110.40300M -83.22100M
Ebitda -179.03700M -148.81600M -115.23800M -96.80000M -75.56300M
Depreciation and amortization 0.22M 0.23M 0.24M 13.60M 7.66M
Non operating income net other - - - - 11.68M
Operating income -179.03700M -178.20500M -136.91900M -110.40300M -83.22100M
Other operating expenses 179.46M 178.21M 136.92M 95.98M 73.57M
Interest expense 4.53M 4.48M 2.20M 6.03M 4.20M
Tax provision -2.47300M 1.59M 0.48M 0.41M 0.20M
Interest income 7.18M 8.27M 4.62M - -
Net interest income 2.67M 3.79M -2.20400M - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -2.47300M 1.59M 0.78M 0.41M 0.20M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 179.04M 178.21M 136.92M 95.98M 73.57M
Cost of revenue 0.22M 0.23M 0.24M - -
Total other income expense net -111.29800M 24.68M 19.23M 19.31M 11.68M
Discontinued operations - - - - -
Net income from continuing ops -287.86200M -155.12200M -116.85800M -91.50500M -71.74200M
Net income applicable to common shares - - - -91.50500M -71.74200M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 210.35M 213.67M 275.99M 197.29M 300.90M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 26.50M 14.39M 11.73M 47.70M 21.62M
Total liab 263.20M 58.97M 50.24M 16.01M 16.49M
Total stockholder equity -52.84800M 154.69M 225.74M 181.28M 284.41M
Deferred long term liab - - - - -
Other current liab 212.94M 14.49M 10.18M 9.32M 0.27M
Common stock 0.97M 0.70M 0.63M 0.44M 0.43M
Capital stock 0.97M 0.70M 0.64M 0.44M 0.43M
Retained earnings -822.59400M -534.73200M -379.61000M -261.14600M -169.64100M
Other liab - - - - -
Good will - - - - -
Other assets - - 0.00000M 2.55M 0.98M
Cash 149.61M 165.08M 220.64M 143.21M 273.24M
Cash and equivalents - - - - -
Total current liabilities 247.79M 34.02M 19.60M 15.60M 15.11M
Current deferred revenue - - 1.12M - 10.04M
Net debt -128.68300M -132.88800M -187.58800M -141.27800M -269.62900M
Short term debt 19.63M 7.24M 2.41M 1.51M 2.23M
Short long term debt 17.52M 5.51M - - -
Short long term debt total 20.93M 32.19M 33.05M 1.93M 3.61M
Other stockholder equity 783.56M 704.92M 621.64M 458.85M 444.78M
Property plant equipment - - - 2.62M 0.40M
Total current assets 191.49M 201.29M 261.30M 191.65M 295.30M
Long term investments - 0.47M 0.47M 0.47M 0.53M
Net tangible assets - - - 181.28M 284.41M
Short term investments - - - - -
Net receivables 15.39M 21.82M 28.93M 15.62M 11.22M
Long term debt 14.11M 24.65M 28.76M - -
Inventory - - 0.00000M -14.87400M -10.78000M
Accounts payable 15.22M 12.28M 5.89M 4.76M 2.56M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -14.78900M -16.19400M -16.92600M -16.86700M 8.84M
Additional paid in capital - - - - -
Common stock total equity - - - - 0.46M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -169.64100M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.73M 5.94M 6.16M 0.33M 0.21M
Deferred long term asset charges - - - - -
Non current assets total 18.86M 12.38M 14.69M 5.64M 5.60M
Capital lease obligations 3.40M 2.03M 4.29M 1.93M 3.61M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.00000M -0.17100M -0.59600M -0.33400M
Change to liabilities - - - 0.80M 5.26M
Total cashflows from investing activities - - -0.06400M -0.59600M -0.33400M
Net borrowings - 0.00000M 29.59M - -
Total cash from financing activities 140.71M 63.82M 173.83M 1.04M 156.65M
Change to operating activities - - - -31.46200M -5.59600M
Net income -287.86200M -155.12200M -118.46400M -91.50500M -71.74200M
Change in cash -15.48300M -55.16800M 77.26M -129.96600M 82.99M
Begin period cash flow 165.47M 220.64M 143.38M 273.35M 190.36M
End period cash flow 149.99M 165.47M 220.64M 143.38M 273.35M
Total cash from operating activities -157.24000M -119.18600M -97.37600M -105.45100M -67.74500M
Issuance of capital stock 140.36M 26.22M 145.42M 0.44M 154.79M
Depreciation 0.22M 0.23M 0.24M 0.33M 0.17M
Other cashflows from investing activities - - 0.00200M - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - -0.00026M - 156.65M
Other cashflows from financing activities -0.32882M 37.60M -0.69000M 0.60M 1.85M
Change to netincome - - - 16.39M 7.78M
Capital expenditures 0.00000M 0.00000M 0.07M 0.60M 0.33M
Change receivables - - - - -
Cash flows other operating - - - - -9.22700M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - 88.57M
Change in working capital -14.28230M 11.72M 3.48M -30.66600M -6.63600M
Stock based compensation 13.59M 19.52M 17.28M 13.12M 8.64M
Other non cash items 131.10M 4.46M 0.09M 3.27M 1.80M
Free cash flow -157.24000M -119.18600M -97.44200M -106.04700M -68.07900M

Peer Comparison

Sector: Healthcare Industry: Medical Care Facilities

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
CMPS
Compass Pathways Plc		 0.67 5.87% 12.08 - - - 16.11 -3.5118
HCA
HCA Healthcare, Inc.		 8.67 2.29% 387.18 13.19 13.66 1.13 293.44 1.77 8.22
FSNUY
Fresenius SE & Co KGaA ADR		 -0.01 0.09% 10.92 16.87 9.44 0.42 0.78 0.79 5.37
JDHIY
JD Health International Inc		 - -% 5.33 62.50 35.97 0.30 2.32 0.16 3.90
JDHIF
JD Health International Inc		 - -% 5.85 57.75 32.68 0.29 2.11 0.16 3.90

Reports Covered

Stock Research & News

View All

Profile

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.

Compass Pathways Plc

33 Broadwick Street, London, United Kingdom, W1F 0DQ

Key Executives

Name Title Year Born
Mr. George Jay Goldsmith Exec. Chairman & Co-Founder 1954
Dr. Ekaterina Malievskaia M.D. Co-Founder, Chief Innovation Officer & Exec. Director 1967
Dr. Guy Goodwin Chief Medical Officer NA
Mr. Kabir Nath M.A., M.B.A. Chief Exec. Officer NA
Mr. Michael F. Falvey Chief Financial Officer 1959
Dr. Greg Ryslik Ph.D. Exec. VP of AI, Engineering, Digital Health Research & Technology NA
Mr. Stephen D. Schultz Sr. VP of Investor Relations NA
Mr. Matthew Owens Gen. Counsel & Chief Legal Officer NA
Mr. Christopher Williams Chief Communications Officer NA
Ms. Anne Benedict Chief People Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.